HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic use of PGA1 infusions in severe pre-eclampsia - a major clinical potential.

Abstract
Pilot studies showed that, i.v. infusions of the renal prostaglandin A1 (PGA1) induced a triad of beneficial clinical responses in severe pre-eclampsia; the blood pressure became normotensive, renal function was markedly improved and labour was successfully induced. The present study was an attempt to develop a therapeutic schedule of PGA1 administration in severe toxemia. Twenty one cases of severe pre-eclampsia (in 3 equal groups) received i.v. infusions of PGA1 in a dose range of 0.1-0.5 microgram/kgm/min for 12 - 24 hours and the B.P., uterine activity and FHR were continuously monitored during and for 12 hours following the infusion period. The 0.1 microgram/Kgm/min dose for 12 hours was inadequate while 0.5 microgram/Kgm/min for 12 hours induced a good hypotensive response and the cases delivered within 48 hours but a post-infusion rebound in hypertension was observed. The dose of 0.5 microgram/Kgm/min for 24 hours appeared to be optimal in clinical terms since a satisfactory effect on B.P. was recorded and all the subjects delivered normal babies during the infusion period with minimal or no post-infusion rebound rise in B.P. This approach holds a major potential in the treatment of severe pre-eclampsia.
AuthorsM K Toppozada, S A Shaala, H A Moussa
JournalClinical and experimental hypertension. Part B, Hypertension in pregnancy (Clin Exp Hypertens B) Vol. 2 Issue 2 Pg. 217-32 ( 1983) ISSN: 0730-0085 [Print] United States
PMID6872285 (Publication Type: Journal Article)
Chemical References
  • Prostaglandins A
  • prostaglandin A1
Topics
  • Adolescent
  • Adult
  • Blood Pressure (drug effects)
  • Female
  • Fetal Heart (physiology)
  • Heart Rate (drug effects)
  • Humans
  • Infant, Newborn
  • Infusions, Parenteral
  • Pre-Eclampsia (drug therapy)
  • Pregnancy
  • Pregnancy Maintenance (drug effects)
  • Prostaglandins A (administration & dosage, adverse effects)
  • Proteinuria (complications)
  • Time Factors
  • Uterine Contraction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: